

Ontario Public Drug Programs

Notice from the Executive Officer: Reimbursement and Claim Submissions for Mifepristone/Misoprostol (Mifegymiso) using the Health Network System

Updated December 7, 2017

This is an update to the original notice dated August 3, 2017.

This notice is to provide information to pharmacies and dispensers about claim submissions and reimbursement for Mifepristone/misoprostol (Mifegymiso), using the Health Network System (HNS).

On August 10, 2017, Ontario began publicly funding the drug Mifegymiso (combination mifepristone/misoprostol).

Overview

On November 7, 2017 Health Canada issued an information update regarding changes to the different requirements and steps that are needed to prescribe, order, stock, and/or dispense Mifepristone/misoprostol (Mifegymiso). The information update is available at:

[http://healthy Canad ians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/65034a-eng.php](http://healthy Canadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/65034a-eng.php) .

Mifegymiso can now be prescribed up to nine weeks (63 days) into a pregnancy, rather than the previous limit of seven weeks (49 days).

- The medication induces a miscarriage-like process and no surgical intervention is required.
- Mifepristone/misoprostol (Mifegymiso) is recognized as a positive step in supporting autonomy for women's reproductive health, provides an alternative to surgical abortions, and expands access to care.

- Mifepristone/misoprostol (Mifegymiso) is manufactured by Linepharma International Limited, and is distributed in Canada by Celopharma Inc.

The Ontario College of Pharmacists (OCP) has also updated its guidance document for its members at www.ocpinfo.com/library/practice-related/download/Dispensing_Mifegymiso.pdf.

There have been no changes to the funding or patient eligibility of mifepristone/misoprostol (Mifegymiso) for Ontarians as a result of these changes.

Patient Eligibility

All Ontarians with a valid Ontario health card number and a valid prescription are eligible for Mifepristone/misoprostol (Mifegymiso).

This includes ODB recipients and non-ODB recipients.

Procedures for Dispensing and Billing

Pharmacists must ensure the eligible person's correct date of birth, health card number and name (as it appears on the Ontario Health Card) are entered accurately as part of the HNS claims submission.

Pharmacy Documentation Requirements

Standard documentation requirements for prescriptions apply. Pharmacists shall keep records consistent with their obligations under the *Pharmacy Act, 1991*, the *Drug and Pharmacies Regulation Act*, and any further instructions provided by the OCP and the ministry.

For billing purposes, pharmacy documentation must be maintained in a readily available format for the purpose of ministry audits for a minimum of 2 years.

Pharmacy Billing Procedure

Mifepristone/misoprostol (Mifegymiso) supplied to patients with a valid prescription will be reimbursed by the ministry. The Drug Identification Number (DIN) is to be used for both ODB-eligible recipients and non-ODB eligible patients for billing purposes.

Pharmacies will be reimbursed for supplying Mifepristone/misoprostol (Mifegymiso) in accordance with the table below.

Table 1: DIN to support reimbursement of Mifepristone/misoprostol (Mifegymiso)

DIN	Description	Total Amount Reimbursed (includes mark-up and dispensing fee)
02444038	Mifepristone/misoprostol (Mifegymiso)	\$337.2500

ODB-eligible Recipients

The claim submission follows the normal process for submitting claims on the HNS with the following additional information:

- Intervention code 'PS': (Professional Care Services)
- Drug Identification Number (DIN): 02444038
- Valid Pharmacist ID
- Professional Fee: \$337.2500 (includes mark-up and dispensing fee)

Non-ODB Eligible Recipients

When submitting a claim for a person who does not have ODB coverage, pharmacists must submit the following information:

- Patient Gender: 'F' = female
- Patient Date of Birth: Valid YYYYMMDD
- Patient's Ontario Health Card number
- Intervention codes:
 - PS: Professional Care Services
 - ML: Established eligibility coverage (i.e., 1 day of the Plan 'S' coverage)
- Carrier ID: 'S'
- Drug Identification Number (DIN): 02444038
- Valid Pharmacist ID
- Professional Fee: \$337.2500 (includes mark-up and dispensing fee)

Restrictions

Only Mifepristone/misoprostol (Mifegymiso) supplied to an eligible patient with a valid prescription will be reimbursed.